Supplementary Figure 1 AXL MER and TYRO3 expression

Supplementary Figure 1. AXL, MER and TYRO-3 expression in Triple Negative Breast Cancer (TNBC) cell lines and PDXs by Western blot analysis. Supplementary Figure 2. AXL m. RNA expression in a large dataset of breast cancer tumors. Tumor were stratified in molecular subtypes using the CIT (Tumor Identity Cards) classification developed in our group (Guedj et al, oncogene, 2012). AXL expression is very variable within each subtype.

Supplementary Figure 3. The 100 genes most correlated with AXL expression in 254 basal-like breast cancers.

A B Supplementary Figure 4. Effect of the anti-AXL monoclonal antibody 20 G 7 -D 9 on matrix degradation by breast cancer cell lines. (A-B) Confocal immunofluorescence analysis of MDA-MB 231 cells cultured on GFP-conjugated gelatin. Matrix degradation is evaluated by quantifying the loss of green fluorescence: number of black spots per cell (A) and digested surface per cell (B). MDA-MB-231 cells were stained with rhodamine phalloidin.

MDA-MB-231 HBL-100 MDA-MB-436 p. AXL TWIST AXL SLUG p. FRA-1 SNAIL FRA-1 VIMENTIN ZEB-1 MMP 1 ZEB-2 MMP 9 MDA-MB-231 HBL-100 MDA-MB-436 Supplementary Figure 5. GAS 6 regulates expression of EMT markers in TNBC - Western Blot quantifications. Protein bands observed on the western blots in Figure 4 were quantified, normalized to GAPDH and relative fold compared to non-treated cells band (NT=1) from each cell line.

Supplementary Figure 6. E-cadherin expression in TNBC cell lines (A). Effect of the anti-AXL monoclonal antibody 20 G 7 -D 9 or irrelevant Px m. Ab on E-cadherin expression in BT 20 cell line stimulated or not with GAS 6 (B).